News Article | September 21, 2017
LONDON--(BUSINESS WIRE)--The partnership will see Ricoh and Alzheimer’s Research co-produce a number of awareness campaigns, leveraging Ricoh’s printing technologies and digital capabilities. Ricoh will also take part in generating much-needed research funding through a series of volunteering activities. The funds raised will support world-class researchers as they work to grow the body of science behind the complex diseases that cause dementia, most commonly Alzheimer’s disease. Participating Ricoh companies in Europe will also host a range of employee engagement and fundraising activities. The sessions will educate staff on the symptoms, causes and impact of dementia, as well as the current progress of research. Javier Diez-Aguirre, Vice President, Corporate Marketing, CSR & Environment, Ricoh Europe, says, “Ricoh shares the mission of Alzheimer’s Research to help bring about the first life-changing dementia treatment by 2025. We are now committing our people, technologies and expertise to contribute to achieving this mission. We are proud of our partnership with Alzheimer’s Research. We can’t wait to put our collective thinking, energy and passion into practice to help defeat dementia.” Timothy Parry, Director of Communications and Partnerships at Alzheimer’s Research, says, “We are proud to unveil our partnership with Ricoh Europe on World Alzheimer’s Day. This is a hugely influential company that leads its field in technical innovation, and through the partnership, Ricoh Europe is demonstrating that corporations of all types can play a meaningful role in overcoming our great medical challenge. We are grateful for the support of Ricoh Europe’s leadership and staff, and through our collaboration we are determined to help enable research breakthroughs that bring hope to individuals and families affected by dementia around the world”. For more information about Alzheimer’s Research, visit www.alzheimersresearchuk.org Ricoh is empowering digital workplaces using innovative technologies and services enabling individuals to work smarter. For more than 80 years, Ricoh has been driving innovation and is a leading provider of document management solutions, IT services, commercial and industrial printing, digital cameras, and industrial systems. Headquartered in Tokyo, Ricoh Group operates in approximately 200 countries and regions. In the financial year ended March 2017, Ricoh Group had worldwide sales of 2,028 billion yen (approx. 18.2 billion USD). For further information, please visit www.ricoh-europe.com Alzheimer’s Research (UK) is the leading dementia research charity in the UK and the largest in Europe, focused on finding preventions, treatments and a cure for dementia. The charity is currently supporting dementia research projects worth nearly £30 million in leading Universities across the UK and around the world. The charity’s Defeat Dementia campaign, a pledge to raise £100 million in five years to grow the research field and accelerate progress towards new treatments and preventions, was announced by David Cameron at the G8 legacy event in 2014, with Mr Cameron subsequently becoming the charity’s President, a voluntary role. For more information visit www.dementiablog.org/defeat-dementia
Kuduk S.D.,Merck And Co. |
Chang R.K.,Merck And Co. |
Di Marco C.N.,Merck And Co. |
Pitts D.R.,Merck And Co. |
And 9 more authors.
Journal of Medicinal Chemistry | Year: 2011
One approach to ameliorate the cognitive decline in Alzheimer's disease (AD) has been to restore neuronal signaling from the basal forebrain cholinergic system via the activation of the M1 muscarinic receptor. A number of nonselective M1 muscarinic agonists have previously shown positive effects on cognitive behaviors in AD patients, but were limited due to cholinergic adverse events thought to be mediated by the activation of the M2 to M5 subtypes. One strategy to confer selectivity for M1 is the identification of positive allosteric modulators, which would target an allosteric site on the M1 receptor rather than the highly conserved orthosteric acetylcholine binding site. Quinoline carboxylic acids have been previously identified as highly selective M1 positive allosteric modulators with good pharmacokinetic and in vivo properties. Herein is described the optimization of a novel quinolizidinone carboxylic acid scaffold with 4-cyanopiperidines being a key discovery in terms of enhanced activity. In particular, modulator 4i gave high plasma free fractions, enhanced central nervous system (CNS) exposure, was efficacious in a rodent in vivo model of cognition, and afforded good physicochemical properties suitable for further preclinical evaluation. © 2011 American Chemical Society.